Skip to main content

and
  1. Article

    Open Access

    Developmental milestones and daily living skills in individuals with Angelman syndrome

    Angelman syndrome (AS) is a neurodevelopmental disorder associated with severe global developmental delay. However, the ages at which different developmental skills are achieved in these individuals remain unc...

    Anjali Sadhwani, Sonya Powers, Anne Wheeler in Journal of Neurodevelopmental Disorders (2024)

  2. No Access

    Article

    Adaptive Skills of Individuals with Angelman Syndrome Assessed Using the Vineland Adaptive Behavior Scales, 2nd Edition

    In the current study, we examined adaptive skills and trajectories over time in 257 individuals with Angelman syndrome (AS) using the Vineland Adaptive Behavior Scales, 2nd Edition. Multilevel linear models we...

    Angela Gwaltney, Sarah Nelson Potter in Journal of Autism and Developmental Disord… (2023)

  3. No Access

    Article

    Developmental Skills of Individuals with Angelman Syndrome Assessed Using the Bayley-III

    We describe the development of 236 children with Angelman syndrome (AS) using the Bayley Scales of Infant and Toddler Development, Third Edition. Multilevel linear mixed modeling approaches were used to explor...

    Anjali Sadhwani, Anne Wheeler in Journal of Autism and Developmental Disord… (2023)

  4. No Access

    Reference Work Entry In depth

    Developmental Disabilities

    Anne Wheeler in Encyclopedia of Quality of Life and Well-Being Research (2023)

  5. No Access

    Chapter

    Premutation-Associated Disorders in Childhood and Adulthood

    This chapter is focused on the medical, developmental, and psychiatric aspects of premutation-associated disorders with the exception of FXTAS and FXPOI, which are covered in other chapters. A historical persp...

    Randi J. Hagerman, Anne Wheeler in FXTAS, FXPOI, and Other Premutation Disord… (2016)

  6. Article

    Open Access

    Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study

    A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutam...

    Donald B. Bailey Jr., Elizabeth Berry-Kravis in Journal of Neurodevelopmental Disorders (2015)

  7. No Access

    Reference Work Entry In depth

    Developmental Disabilities

    Anne Wheeler in Encyclopedia of Quality of Life and Well-Being Research (2014)